Semaglutide is a GLP-1 receptor agonist FDA-approved as Ozempic (diabetes), Wegovy (obesity), and Rybelsus (oral diabetes). It reduces appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion. Weekly injectable formulation provides sustained GLP-1 activation. Semaglutide produced approximately 15-17% body weight loss in clinical trials, revolutionizing obesity treatment. It is a single-agonist (GLP-1 only) compared to tirzepatide (dual GLP-1/GIP) and retatrutide (triple GLP-1/GIP/glucagon).
Quick Start
Route
SubQ injection (weekly)
Start low
0.25 mg SubQ
Frequency
Once weekly
Timing
No fasting required
Starting dose. 0.25 mg — Weekly, titrating up
SubQ: Any time, any day, with or without food. Once weekly on the same day. Oral (Rybelsus): Must be taken on empty stomach with no more than 4oz water, 30 minutes before food/drink/other meds.
❋
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Tiered Protocols · lowest first
Conservative start
0.25 mg weekly, titrating up · SubQ injection (weekly) · Once weekly
Each reference below was re-fetched from its PubMed record, and the quoted sentence was
confirmed to appear in that abstract and to support the claim it sits under. Follow any of
them to read the source.
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation.
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation.
Evidence scope. Safety review; confirms both marketed routes but not the card's 0.25 mg titration schedule.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the
same as saying they are false — it marks where the evidence is missing.
Complete regimen: 0.25 mg weekly, titrating up via SubQ injection (weekly), Once weekly. The verified row supports only the narrower dose/route boundary stated above, not every element of the displayed regimen.
Mechanism: Semaglutide binds GLP-1 receptors in the pancreas (enhancing glucose-dependent insulin secretion), hypothalamus (suppressing appetite), and GI tract (slowing gastric emptying). Albumin binding extends half-life to approx. No checked live abstract supported this full mechanistic claim at the card's formulation/route without extrapolation.
Primary safety claim: Nausea. No checked live abstract directly established this as the primary concern for the card's exact formulation and regimen.
04
The honest take
◆
Cardiovascular benefit
SELECT trial showed 20% reduction in major cardiovascular events. First GLP-1 with dedicated CV outcome data in obesity.
15-17% weight loss
Confirmed across STEP trial program. FDA-approved for chronic weight management.
05
Interactions & stacking
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
◆
Pin alone. Semaglutide must not share a syringe with anything else, whatever the pharmacology says.
PIN ALONE. GLP-1 class.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
06
Side effects & safety
Commonly reported
Nausea
Diarrhea
Constipation
Decreased appetite
Vomiting during titration
Less common & notes
Pancreatitis risk (class effect).
Gallbladder issues.
Gastroparesis.
Thyroid C-cell tumor signal in rodents.
Contraindicated with MTC/MEN2 history.
Oral contraceptives may be less reliable during dose initiation and escalation: delayed gastric emptying (GLP-1 / amylin) can reduce oral drug absorption - Tirzepatide carries an FDA label warning to use a backup or non-oral method for 4 weeks after starting and after each dose increase.
07
Pharmacokinetics
Illustrative plasma concentration · 29 d
Half-life
168h
Peak · Tmax
24h
Elimination
840h
Bioavailability
~89%
SubQ
Duration of action
7 days
Supports weekly dosing; appetite suppression sustained between doses
Clearance
Enzymatic degradation and renal elimination (albumin-bound, slow turnover)
Storage. Pre-filled pens: 56 days room temp. Compounded: 28 days 2-8C.
08
Regulatory status
FDA-approved as Ozempic, Wegovy, Rybelsus. WADA prohibited under S4 in competition. Schedule varies by country.
Put it to work
Calculate, log & track
Open Semaglutide straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.